¿À±¹È¯¡¤°û ö¡¤°­Àç½Â ±³¼ö ¡®°úÇбâ¼ú¿ì¼ö³í¹®»ó¡¯ ¼ö»ó

´º½ºÀÏÀÚ: 2012³â07¿ù05ÀÏ 00½Ã00ºÐ

¿À±¹È¯ ±³¼ö

°û ö ±³¼ö

°­Àç½Â ±³¼ö

¼­¿ï´ëº´¿ø ³»°ú ¿À±¹È¯ ±³¼ö, ºñ´¢±â°ú °û ö ±³¼ö, ¼­¿ïÀÇ´ë ÇغÎÇб³½Ç °­Àç½Â ±³¼ö°¡ 5ÀÏ °úÇбâ¼ú¿ì¼ö³í¹®»ó'À» ¼ö»óÇß´Ù.

À̳¯ ÀÌµé ±³¼ö´Â ¼­¿ï ÄÚ¿¢½º¿¡¼­ ¿­¸° ‘2012³âµµ ´ëÇѹα¹°úÇбâ¼ú¿¬Â÷´ëȸ’¿¡¼­ ±³À°°úÇбâ¼úºÎ¿Í Çѱ¹°úÇбâ¼ú´ÜüÃÑ¿¬ÇÕȸ°¡ ½Ã»óÇÏ´Â 'Á¦22ȸ °úÇбâ¼ú¿ì¼ö³í¹®»ó'À» ¹Þ¾Ò´Ù.

°úÇбâ¼ú¿ì¼ö³í¹®»óÀº Çѱ¹°úÇбâ¼ú´ÜüÃÑ¿¬ÇÕȸ°¡ Áö³­ ÇÑ ÇØ µ¿¾È ÀǾàÇкоߴ ¹°·Ð, °øÇÐ, ÀÚ¿¬°úÇÐ µî °úÇÐ Àü ºÐ¾ß¿¡¼­ ¹ßÇ¥µÈ ³í¹®µé Áß °¢ 1Æí¾¿À» Çùȸ »êÇÏ ÃÑ 368°³ ÇÐȸ·ÎºÎÅÍ ÃßõÀ» ¹Þ¾Æ ¾ö°ÝÇÑ ½É»ç¸¦ °ÅÃÄ ¼±Á¤µÈ ¼ö»óÀÚ¿¡°Ô ¼ö¿©µÈ´Ù.

¿À±¹È¯ ±³¼ö´Â Àå±â°£ º¹¸·Åõ¼®À» ½ÃÇà ¹ÞÀº ȯÀÚ¿¡°Ô¼­ ³ªÅ¸³ª´Â º¯¼º Çö»óÀ» Á¶Á÷ ³»¿¡¼­ aquaporin°ú VEGF/VEGF receptor ¹°ÁúÀÇ º¯È­¸¦ ÅëÇØ ±Ô¸íÇÑ “Expression of Aquaporin-1, Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 in the Peritoneal Tissues of Peritoneal Dialysis Patients”¶õ ³í¹®À» ¹ßÇ¥, ¼ö»óÀÚ°¡ µÆ´Ù.

°û ö ±³¼ö´Â ¹æ±¤¾Ï¿¡¼­ À¯ÀüÀÚº¯Çü Ç÷°ü³»ÇǼ¼Æ÷¸¦ ÀÌ¿ëÇÑ Ç׾Ϲé½Å°ú GM-CSFÀÇ Åõ¿©°¡ ¹æ±¤¾ÏÀÇ ½Å»ýÇ÷°üÇü¼ºÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ç×¾ÏÈ¿°ú¸¦ °¡Áø´Ù´Â »ç½ÇÀ» ¹àÇô³ÂÀ¸¸ç À̸¦ imatinibÀ̶ó´Â ¾à¹°°ú º´ÇÕ½ÃÄÑ »ç¿ëÇÏ¸é »ó½ÂÈ¿°ú¸¦ °®´Â´Ù´Â "Combined treatment with anticancer vaccine using genetically modified endothelial cells and imatinib in bladder cancer"¶ó´Â ³í¹®À» ¹ßÇ¥, °ø·Î°¡ ÀÎÁ¤µÆ´Ù.

°­Àç½Â ±³¼ö´Â Áö³­ 1999³âºÎÅÍ ¿ì¸® ¸ö¿¡¼­ ¿°Áõ¹ÝÀÀÀ» ÀÏÀ¸ÄÑ Á¾¾ç ¹ß»ý°ú ¼ºÀå¿¡ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ´Â CM1À̶ó´Â ¹°Áú ±Ô¸í¿¡ ³ª¼­ Æ÷µµ´ç´ë»ç °úÁ¤ Áß¿¡ ÀÛ¿ëÇÏ´Â Áß¿äÇÑ È¿¼Ò ¿¡³î·¹ÀÌÁî(enolase)ÀÎ °ÍÀ» "Identification of CM1 as a pathogenic factor in inflammatory diseases and cancer"¶ó´Â ³í¹®À» ÅëÇØ ¹ßÇ¥ÇÑ °ø·Î°¡ ÀÎÁ¤µÆ´Ù
 

 

 

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.